anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a novel component that exhibits a retinoid-like action and a collagen production-promoting action and inhibits formation of wrinkles by increasing the thickness of the dermis.SOLUTION: (1) The collagen production promoter contains an extract from a plant belonging to the genus Fragaria of the family Rosaceae as an effective ingredient. (2) The collagen production promoter as described in (1), where a seed is used as a portion of the plant belonging to the genus Fragaria of the family Rosaceae. (3) The collagen production promoter contains an extract from a seed of a litchi as an effective ingredient. (4) The collagen production promoter contains an extract from a plant belonging to the genus Juglans of the family Juglandaceae as an effective ingredient. (5) The retinoid-like action-activating agent contains an extract from a plant belonging to the genus Juglans of the family Juglandaceae as an effective ingredient. (6) The dermis growth promoter contains an extract from a seed of a plant belonging to the genus Fragaria of the family Rosaceae as an effective ingredient.
Early life adversity (ELA) is associated with earlier initiation and maintenance of tobacco smoking and with a greater risk of subsequent relapse. There is growing evidence that appetite hormones, including peptide YY (PYY), which modulates craving and satiety responses, play a role in stress and addiction processes. This study employed a quasi-experimental design to examine the association between ELA and circulating PYY stress responses in smokers and nonsmokers (N = 152, ages 19-73 years) to examine the effects of nicotine addiction. Smokers initiated a quit attempt as part of the study and were classified as either abstinent smokers or relapsed smokers based on their nicotine use during the follow-up period. PYY levels were measured at five timepoints during three lab sessions and compared between nonsmokers and the two smoking groups (abstainers, relapsers): while smokers were using nicotine ad libitum, 24 h after smokers initiated a quit attempt, and 4 weeks after smokers initiated a quit attempt. Multivariate analyses showed the main effects of time on PYY, which decreased over time within each session. The main effects of ELA during the first (ad libitum smoking) and second (24-h post-cessation for smokers) sessions indicated that experiencing ELA was associated with lower PYY. No systematic effect of nicotine addiction or relapse was observed in this study. These findings suggest that adults with higher ELA may experience lower PYY. Additional research is needed to further explore the role of PYY in stress and addiction processes.
Risk Summary 

No adequate human data are available to establish whether or not ZEPATIER poses a risk to pregnancy outcomes. In animal reproduction studies, no evidence of adverse developmental outcomes was observed with the components of ZEPATIER (elbasvir or grazoprevir) at exposures greater than those in humans at the recommended human dose (RHD) (see Data). During organogenesis in the rat and rabbit, systemic exposures (AUC) were approximately 10 and 18 times (for elbasvir) and 117 and 41 times (for grazoprevir), respectively, the exposure in humans at the RHD. In rat pre/postnatal developmental studies, maternal systemic exposures (AUC) to elbasvir and grazoprevir were approximately 10 and 78 times, respectively, the exposure in humans at the RHD.

The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

If ZEPATIER is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. Refer to the ribavirin prescribing information for more information on use in pregnancy.

Data

Animal Data 

Elbasvir: Elbasvir was administered orally at up to 1000 mg/kg/day to pregnant rats and rabbits on gestation days 6 to 20 and 7 to 20, respectively, and also to rats on gestation day 6 to lactation/post-partum day 20. No effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at up to the highest dose tested. Systemic exposures (AUC) to elbasvir were approximately 10 (rats) and 18 (rabbits) times the exposure in humans at the RHD. In both species, elbasvir has been shown to cross the placenta, with fetal plasma concentrations of up to 0.8% (rabbits) and 2.2% (rats) that of maternal concentrations observed on gestation day 20. 

Grazoprevir: Grazoprevir was administered to pregnant rats (oral doses up to 400 mg/kg/day) and rabbits (intravenous doses up to 100 mg/kg/day) on gestation days 6 to 20 and 7 to 20, respectively, and also to rats (oral doses up to 400 mg/kg/day) on gestation day 6 to lactation/post-partum day 20. No effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at up to the highest dose tested. Systemic exposures (AUC) to grazoprevir were ≥78 (rats) and 41 (rabbits) times the exposure in humans at the RHD. In both species, grazoprevir has been shown to cross the placenta, with fetal plasma concentrations of up to 7% (rabbits) and 89% (rats) that of maternal concentrations observed on gestation day 20.
Immune-mediated necrotizing myopathy (IMNM) is a rare and newly recognized autoimmune disease within the spectrum of idiopathic inflammatory myopathies. It is characterized by myositis-specific autoantibodies, elevated serum creatine kinase levels, inflammatory infiltrate, and weakness. IMNM can be classified into three subtypes based on the presence or absence of specific autoantibodies: anti-signal recognition particle myositis, anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myositis, and seronegative IMNM. In recent years, IMNM has gained increasing attention and emerged as a research hotspot. Recent studies have suggested that the pathogenesis of IMNM is linked to aberrant activation of immune system, including immune responses mediated by antibodies, complement, and immune cells, particularly macrophages, as well as abnormal release of inflammatory factors. Non-immune mechanisms such as autophagy and endoplasmic reticulum stress also participate in this process. Additionally, genetic variations associated with IMNM have been identified, providing new insights into the genetic mechanisms of the disease. Progress has also been made in IMNM treatment research, including the use of immunosuppressants and the development of biologics. Despite the challenges in understanding the etiology and treatment of IMNM, the latest research findings offer important guidance and insights for delving deeper into the disease's pathogenic mechanisms and identifying new therapeutic strategies.
Participants randomised to the intervention group will complete an 8-week bladder and PFMT programme, both at the LSCIC and at home. They will be invited to 3 face-to-face follow up appointments over the 8-weeks, where they will meet with a physiotherapist to check their technique and monitor their progress. At home participants will receive a daily text reminder to complete their PFM training, they will also receive a weekly phone call from a member of the research team who will check how they are managing and whether they have any questions. At the end of the programme, participants will be asked to repeat the questionnaires and have their pelvic floor re-assessed. Following this, they will complete the urodynamic investigation with tSCS.
Hispanics, a group that shows higher type 2 diabetes (T2D) prevalence, and poor self-management and clinical outcomes, have been disproportionally adversely impacted by COVID-19. The California Department of Public Health reports that Hispanics make up 39% of California's population but an unprecedented 57% of the confirmed COVID-19 cases. This devastating finding is especially notable on the US/Mexico border. Diabetes has emerged as a leading risk factor for severe COVID-19 illness leading to hospitalization, is associated with greater disease severity and mortality and is an independent predictor of intensive care placement and invasive ventilation. It is becoming increasingly clear that maintaining good glucose control improves prognosis of COVID-19 among people with pre-existing T2D. However, social distancing, quarantine, and stay-at-home/lockdown guidelines may impact one's ability to maintain adequate glycemic control. Research is needed to evaluate the effect and clinical outcomes of a flexible, easily adopted low cost digital intervention that improves glucose excursions and provides urgently needed COVID-19 mitigation strategies, among rapidly rising groups of high-risk Hispanics with poorly controlled T2D in US/Mexico border communities. Strong evidence from our parent grant Dulce Digital-Me (DD-ME), supports the use of technology (such as text messaging) alone or in combination with coaching interventions as a viable and desired method of delivering tailored diabetes self-management education and COVID awareness messaging to high-risk, underserved populations in a manner that is more convenient for both patients and staff while having the added benefit of being cost-effective for health systems, especially within low resource settings. However, effective interventions may encounter barriers which preclude guaranteed success upon implementation in the real world. This project, taking place along the San Diego/Tijuana border, historically the busiest land port of entry in the Western Hemisphere, will assess the effect of providing an enhanced digital texting intervention-Dulce Digital-COVID Aware (DD-CA) to N = 172 Hispanic patients with T2D upon discharge from a recent hospitalization. Key outcomes will assess the impact of DD-CA on hospital readmissions at 30, 90 and 180 days post-discharge, glucose control and patient reported outcomes at 90 and 180 days post-discharge while also assessing COVID status and the implementation process. Given that DD-CA offers the potential to address many of the practical barriers to access and extend the reach of diabetes services, while additionally providing COVID awareness support, it offers an ideal low-cost and flexible solution to reduce hospital admissions and re-admissions in US/Mexico border communities significantly and simultaneously affected by COVID-19 and T2D. Implemented in a typical hospital and post-discharge setting, it augments existing care team processes, thus providing a valuable test of real-world effectiveness. More importantly, by helping to reduce existing inequities in access to diabetes and COVID-19 care, this program aims to improve health outcomes on a larger scale.
The invention provides compositions and methods for diagnosing and treating reproductive disorders. The invention also provides methods for diagnosing reproductive disorders by detecting the presence of IFN-.gamma. in the semen of a prospective father, which is indicative of the presence of a reproductive disorder. In particular, the invention provides a method for treating a reproductive disorder in a mammal, comprising administering an effective amount of a compound which inhibits the activity of IFN.gamma. to the mammal.  The mammal may be the prospective mother or the prospective father.
The invention discloses a traditional Chinese medicinal composition and a preparation method thereof. The composition is prepared from the following traditional Chinese medicines in parts by weight: 22-28 parts of scutellaria baicalensis, 22-25 parts of fructus forsythiae, 8-10 parts of coptidis rhizoma, 35-42 parts of cortex phellodendri, 22-28 parts of red peony root, and 8-12 parts of liquorice. The preparation method comprises the following steps: crushing, extracting, concentrating, drying, and crushing and pelleting. Medicines of the traditional Chinese medicinal composition are combined and compatible to achieve the effects of clearing heat and removing toxicity, diminishing swelling and relieving pain, and can be used in treatment of stagnant heat in organs, headache and conjunctival congestion, ulcer in dental cavity and nose, abdominal pain due to pyretic dysentery, leukorrhea due to damp heat and pathopyretic sore edema. The method by adopting mixing preparation comprises the following steps: crushing red peony root and coptidis rhizoma; mixing scutellaria baicalensis, fructus forsythiae, cortex phellodendri and liquorice, extracting with water for multiple times, mixing with the powdered medicine to prepare pellets. According to the traditional Chinese medicinal composition, the drug effect is further improved, the range of applicable people is enlarged, the production process is reduced, and the production cost is reduced.
Subjects will first be ventilated with the TTIP technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1). Subjects will then be ventilated with mask ventilation (Step 2). In Step 1, if ventilation fails with the TTIP technique for all of the first three consecutive breaths, the subject will be crossed over to the mask ventilation. If ventilation fails again with all the first three consecutive breaths after crossover, the study will be terminated. The routine care is resumed including tracheal intubation or laryngeal mask airway (LMA) insertion.
Anthracycline antibiotics, namely, doxorubicin (DOX) and daunorubicin, are among the most widely used anticancer therapies, yet are notoriously associated with severe myocardial damage due to oxidative stress and mitochondrial damage. Studies have indicated the strong pharmacological properties of Berberine (Brb) alkaloid, predominantly mediated via mitochondrial functions and nuclear networks. Despite the recent emphasis on Brb in clinical cardioprotective studies, pharmaceutical limitations hamper its clinical use. A nanoformulation for Brb was developed (mMic), incorporating a cationic lipid, oleylamine (OA), into the TPGS-mixed corona of PEGylated-phosphatidylethanolamine (PEG-PE) micelles. Cationic TPGS/PEG-PE mMic with superior Brb loading and stability markedly enhanced both intracellular and mitochondria-tropic Brb activities in cardiovascular muscle cells. Sub-lethal doses of Brb via cationic OA/TPGS mMic, as a DOX co-treatment, resulted in significant mitochondrial apoptosis suppression. In combination with an intense DOX challenge (up to ~50 µM), mitochondria-protective Brb-OA/TPGS mMic showed a significant 24 h recovery of cell viability (p ≤ 0.05-0.01). Mechanistically, the significant relative reduction in apoptotic caspase-9 and elevation of antiapoptotic Bcl-2 seem to mediate the cardioprotective role of Brb-OA/TPGS mMic against DOX. Our report aims to demonstrate the great potential of cationic OA/TPGS-mMic to selectively enhance the protective mitohormetic effect of Brb to mitigate DOX cardiotoxicity.
The novel positively charged pro-drugs of diclofenac in the general formula (1), with X = O or S, were designed and synthesized. The compounds of the general formula (1) can be prepared from functional derivatives of diclofenac by reaction with suitable alcohols, thiols, or amines. The positively charged amino groups of these pro-drugs not only largely increase the solubility of the drugs in water, but also bond to the negative charge on the phosphate head group of membranes and push the pro-drug into the cytosol. Experimental results suggest that the pro-drug diethylaminoethyl 2[(2,6-dichlorophenyl)amino]benzene acetate.AcOH diffuses through human skin 250 times faster than 2[(2,6-dichlorophenyl)amino]benzene acetic acid (diclofenac) and ethyl 2[(2,6-dichlorophenyl)amino]benzene acetate. In plasma, more than 90% of these pro-drugs can change back to the drug in a few minutes. The prodrugs can be used medicinally in treating any diclofenac-treatable conditions in humans or animals and be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of diclofenac, most notably GI disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled transdermal administration systems of the prodrug enables diclofenac to reach constantly optimal therapeutic blood levels to increase effectiveness and reduce the side effects of diclofenac.
The invention discloses a traditional Chinese medicine for treating cholecystitis. The traditional Chinese medicine comprises the following raw materials in parts by weight: 8 parts of white paeony root, 8 parts of fructus aurantii, 6 parts of elecampane, 6 parts of rhizoma corydalis, 9 parts of rhizoma alismatis, 6 parts of the root of bidentate achyranthes, 6 parts of oriental wormwood, 10 parts of bighead atractylodes rhizome, 8 parts of rhizoma anemarrhenae, 6 parts of the seed of Chinese dodder, 10 parts of lalang grass rhizome, 10 parts of liquorice, 6 parts of herba pyrrosiae, 6 parts of chingma abutilon seed and 10 parts of Lysimachia christinae Hance. The decoction preparation method comprises the following steps: weighing the raw materials according to a formula ratio, adding the materials into an extraction container, extracting in water at the temperature of 100 DEG C for an hour, filtering, separating, thereby obtaining the extracting solution. One dose of the decoction is taken per day and is taken twice, and a course of treatment refers to one month. The medicine is taken within 1-2 courses of treatment, and according to clinical treatment observation of more than 60 patients suffering from cholecystitis, the effective rate is 97.2 percent, the cholecystitis can be effectively treated, and the effects of treating the cholecystitis and conditioning the body are achieved. Moreover, the traditional Chinese medicine is convenient in administration and extract in curative effect, and the surgical pain and economical burdens of the patients can be alleviated. The traditional Chinese medicine is applied to production in pharmaceutical factories, clinical application in hospitals and administration of patients.
The ratio of arterial spin labeled (ASL) perfusion to diffusion weighted imaging (DWI) is generally homogeneous in the anoxic/hypoxic injury population. Conversely, the ratio is more heterogeneous in the non-anoxic/hypoxic population. By plotting these ratios in a graphical format in the form of an axial color map of the brain—referred to as a normalized diffusion to perfusion (NDP) ratio colormap—it may be determined whether a patient has suffered from an anoxic/hypoxic injury. Thus, the anoxic and non-anoxic injury patients will have, respectively, homogenous and heterogeneous color maps. Anoxic brain injury patients have a global homogeneously positive relationship between qualitative ASL perfusion and diffusion weighted signal such that areas of restricted diffusion show significantly increased ASL perfusion signal, which may be attributable to BBB integrity. The NDP ratio colormap provides an imaging biomarker to differentiate anoxic brain injury from normal controls and to potentially assess BBB integrity.
Lithium carbonate 400 mg capsules will be taken once daily, starting with one capsule (400 mg daily) initially titrated up to two or three capsules daily, depending on blood lithium levels. The target range for the lithium plasma level will be between ≥0.4 mmol/l and ≤ 0.8 mmol/l. Maximum duration is 24 months.
INTRODUCTION: Presacral neuroendocrine neoplasms (PNENs) are rare tumors, with limited data on management and outcomes.
METHODS: A retrospective review of institutional medical records was conducted to identify all patients with PNENs between 2008 and 2022. Data collection included demographics, symptoms, imaging, surgical approaches, pathology, complications, and long-term outcomes.
RESULTS: Twelve patients were identified; two-thirds were female, averaging 44.8 years of age, and, for the most part, presenting with back pain, constipation, and abdominal discomfort. Preoperative imaging included computed tomography scans and magnetic resonance images, with somatostatin receptor imaging and biopsies being common. Half of the patients had metastatic disease on presentation. Surgical approach varied, with anterior, posterior, and combined techniques used, often involving muscle transection and coccygectomy. Short-term complications affected one-quarter of patients. Pathologically, PNENs were mainly well-differentiated grade 2 tumors with positive synaptophysin and chromogranin A. Associated anomalies were common, with tail-gut cysts prevalent. Mean tumor diameter was 6.3 cm. Four patients received long-term adjuvant therapy. Disease progression necessitated additional interventions, including surgery and various chemotherapy regimens. Skeletal, liver, thyroid, lung, and pancreatic metastases occurred during follow-up, with no mortality reported. Kaplan-Meier analysis showed a 5-year local recurrence rate of 23.8%, disease progression rate of 14.3%, and de novo metastases rate of 30%.
CONCLUSION: The study underscores the complex management of PNENs and emphasizes the need for multicenter research to better understand and manage these tumors. It provides valuable insights into surgical outcomes, recurrence rates, and overall survival, guiding future treatment strategies for PNEN patients.
The invention provides a traditional Chinese medicine used for treating second degree burn, and a preparation method thereof. The traditional Chinese medicine is prepared from, root of daphniphyllum calycinum benth., root or stem of evergreen mucuna, all-grass of achyranthes aspera L., all-grass of helwingia japonica (thunb.) dietr., salvia evansiana, rabdosia japonica (burm. f.)Hara var. glaucocalyx (maxim.) hara, all-grass of oxalis acetosella L., herb of twinleaf zornia, herb of adder tongue, herb of adjoin clinopodium, phyllodium pulchellum (L.) desv.[desmodium pulchellum (L.) benth, aralia apioides hand.-mazz. root, and rhizoma ardisiae gigantifoliae. Beneficial effects are that: the traditional Chinese medicine possesses exact curative effects on second degree burn, less side effect is caused, second degree burn can be treated in a shorter time, and the pain of patients is reduced.
ddC has been shown to demonstrate an antiviral effect. AZT has been shown to significantly decrease mortality and reduce the frequency of opportunistic infections in patients with AIDS or advanced ARC. After 1 year of AZT therapy, the effectiveness tends to diminish and patients progress with more opportunistic infections and higher mortality rates. Because of the demonstrated antiviral activity, absence of hematologic toxicity, and lack of cross tolerance in laboratory studies of ddC, a study to investigate the long-term effectiveness of ddC in patients with HIV infection who have received AZT therapy is warranted.

Patients are randomly assigned to 1 of 3 treatment groups. In study arm 1, patients receive AZT plus ddC placebo. In study arm 2, patients receive ddC plus AZT placebo capsules. In study arm 3, patients receive ddC plus AZT. Patients are seen every other week for first 8 weeks and monthly thereafter. Patients are stratified by HIV disease status, length of time receiving AZT, and systemic or local Pneumocystis carinii pneumonia (PCP) prophylaxis. Patients who reach a clinical AIDS-defining endpoint are offered open-label combination therapy.
One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.